25 March 2025
AOTI, INC. (the "Company" or "Group" or "AOTI")
Director/PDMR Shareholding - transfer of shares to SIPP
The Company was informed on 25 March 2025 that Mr Douglas Lefort, Non-executive Chairman of the Company and his spouse, transferred a total of 361,453 common shares of $0.00001 each in the capital of the Company ("Common Shares") into their Self-Invested Personal Pensions ("SIPPs") from their jointly owned consulting vehicle, Wolfpack Consulting Limited. This was effected by the purchase and sale of 194,117 Common Shares at 102.5 pence each on 20 March 2025 by Mr Lefort and the purchase and sale of 167,336 Common Shares at 95 pence each on 25 March 2025 by Mrs Lefort.
Following the purchase and sale transactions, there is no change to Mr Lefort's beneficial holding (including that of his spouse) and the total interest in the Company remains the same at 1,451,621 Common Shares, representing approximately 1.36% of the Company's issued share capital.
The below notification, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.
END
For further information please contact:
| AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
| Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
| FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis
|
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||
| a)
| Name
| 1. Mr Douglas Lefort 2. Mrs Gillian Lefort | ||||||||||
| 2
| Reason for the notification
| |||||||||||
| a)
| Position/status
| 1. Non-executive Chairman 2. PCA of Douglas Lefort | ||||||||||
| b)
| Initial notification /Amendment
| Initial notification | ||||||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||
| a)
| Name
| AOTI Inc. | ||||||||||
| b)
| LEI
| 213800ZGCNDSTWIRK687 | ||||||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||
| a)
| Description of the financial instrument, type of instrument
Identification code
| Common shares of $0.00001 each
ISIN: US03690C1027 | ||||||||||
| b)
| Nature of the transaction
| 1. Purchase of Common Shares into Mr Lefort's SIPP on 20 March 2025 2. Sale of Common Shares by Mr Lefort on 20 March 2025 3. Purchase of Common Shares into Mrs Lefort's SIPP on 25 March 2025 4. Sale of Common Shares by Mrs Lefort on 25 March 2025
| ||||||||||
| c)
| Price(s) and volume(s) |
| ||||||||||
| d)
| Aggregated information
- Aggregated volume
- Price
|
361,453
99.03p | ||||||||||
| e)
| Date of the transaction
| 1, 2 - 20 March 2025 3,4 - 25 March 2025 | ||||||||||
| f)
| Place of the transaction
| London Stock Exchange | ||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
